Dyslipidemia in diabetic nephropathy

4^th International Conference on Nephrology & Therapeutics

September 14-16, 2015 Baltimore, USA

Nasir Yunus Fulara

Grant Medical College & Sir Jamshedjee Jeejeebhoy Group of Hospitals, India

Scientific Tracks Abstracts: J Nephrol Ther

Abstract :

Diabetic nephropathy is the leading cause of kidney disease in patients starting renal replacement therapy and affects about 40% of Type 1 and Type 2 diabetic patients. It increases the risk of death mainly from cardiovascular causes and is defined by increased urinary albumin excretion in the absence of other renal diseases. Hyperglycemia, increased blood pressure levels and genetic predisposition are the main risk factors for the development of diabetic nephropathy. Recent epidemiological research revealed that dyslipidemia is also a risk factor for development and progression of diabetic nephropathy. The effect of Dyslipidemia on renal function can be explained by �lipid nephrotoxicity� hypothesis. Under this hypothesis, mesangial proliferation caused by accumulation of lipoprotein into mesangial cells induces glomerulosclerosis. This theory has been updated recently including the concept of inflammation stress modifying lipid homeostasis and tissue lipid accumulation. Evidence from recent studies has suggested that dyslipidemia is one of the risk factors for progression and regression of diabetic nephropathy. But, there have been few studies reporting the association with end-stage renal disease or renal replacement therapy. Long-term follow-up studies are needed to demonstrate the causal relationships between dyslipidemia and end-stage renal disease from diabetic nephropathy. With regard to the treatment of dyslipidemia in patients with diabetes, there were some interventional trials of anti-hypercholesterolemic agents including fibrates and statins suggesting that these drugs are effective in lowering the decline of the estimated Glomerular Filtration Rate (eGFR) and reducing the progression of albuminuria.

Biography :

Nasir Yunus Fulara is a Professor of Medicine at Delhi National Board and Medical Research Centre. He is also serving as a Senior Physician, Cardiologist & Diabetologist at Jaslok Hospital & Medical Research Centre Mumbai, Saifee Hospital Mumbai and Breach Candy Hospital & Medical Research Centre Since last 34 years till date. He is also attached to Wockhardt Hospital- Mumbai South, an association with Partners Medical International (PMI) Boston, USA. He has also served as a Professor of Advanced Medicine at Tibbia Medical College in Mumbai. He has published in Nephrology Journals and papers in Indian Journals of Nephrology. He is a respected Member of American Diabetic Association (ADA), European Association for Study of Diabetes (EASD) and Opinion Leader from India in International Diabetic Forum (IDF), Association of Physician of India (API) and Research Society for the Study of Diabetes in India (RSSDI). He was conferred the fellowship of the Texas Institute of Heart-Houston, The German Diabetes Center-Germany, AMI Group of Hospital-London. He has been awarded with prestigious Best Physician, Rajiv Gandhi Gold Medal Award in 1992.

Email: fmcbom@gmail.com